DALLAH HEALTHCARE COMPANY |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 160.8 SAR | -2.55% |
|
-2.07% | -6.40% |
| 06-12 | Dallah Healthcare Maintains Q1 Dividend | MT |
| 05-15 | Dallah Healthcare Company Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,335 | 4,126 | 6,759 | 13,320 | 16,782 | 15,707 | - | - |
| Enterprise Value (EV) 1 | 4,287 | 5,510 | 8,440 | 15,060 | 18,520 | 17,412 | 17,383 | 16,954 |
| P/E ratio | 23.2 x | 42.7 x | 26.2 x | 48.5 x | 46.4 x | 36.4 x | 30.5 x | 27.2 x |
| Yield | 2.56% | 1.55% | 2% | - | - | 1.52% | 1.86% | 1.9% |
| Capitalization / Revenue | 2.66 x | 3.13 x | 3.21 x | 5.35 x | 5.7 x | 4.75 x | 4.41 x | 4.11 x |
| EV / Revenue | 3.42 x | 4.18 x | 4.01 x | 6.05 x | 6.29 x | 5.27 x | 4.88 x | 4.43 x |
| EV / EBITDA | 17.4 x | 25 x | 19.1 x | 28.1 x | 29.3 x | 24.9 x | 22.4 x | 20.2 x |
| EV / FCF | 40.4 x | 102 x | 34.3 x | 55.9 x | 55.9 x | 60.1 x | 48.8 x | 33.8 x |
| FCF Yield | 2.47% | 0.98% | 2.91% | 1.79% | 1.79% | 1.66% | 2.05% | 2.96% |
| Price to Book | 2.23 x | 2.36 x | 3.62 x | 6.69 x | 4.82 x | 4.43 x | 4.15 x | 3.89 x |
| Nbr of stocks (in thousands) | 85,512 | 85,512 | 90,000 | 90,000 | 97,681 | 97,681 | - | - |
| Reference price 2 | 39.00 | 48.25 | 75.10 | 148.0 | 171.8 | 160.8 | 160.8 | 160.8 |
| Announcement Date | 01/03/20 | 25/03/21 | 22/03/22 | 20/03/23 | 14/03/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,252 | 1,318 | 2,105 | 2,488 | 2,943 | 3,305 | 3,560 | 3,824 |
| EBITDA 1 | 247.1 | 220.2 | 443 | 536.7 | 631.9 | 698.2 | 775.5 | 837.7 |
| EBIT 1 | 154.4 | 125.2 | 365 | 422.4 | 506.3 | 567.9 | 618.2 | 661.4 |
| Operating Margin | 12.33% | 9.49% | 17.34% | 16.98% | 17.2% | 17.19% | 17.37% | 17.3% |
| Earnings before Tax (EBT) 1 | 151.6 | 113.5 | 291.8 | 329.1 | 400.3 | 501 | 578.6 | 638.1 |
| Net income 1 | 146.9 | 97.13 | 258.6 | 274.5 | 360.1 | 436.2 | 513.2 | 601.7 |
| Net margin | 11.73% | 7.37% | 12.29% | 11.03% | 12.24% | 13.2% | 14.42% | 15.73% |
| EPS 2 | 1.683 | 1.130 | 2.870 | 3.050 | 3.700 | 4.418 | 5.280 | 5.910 |
| Free Cash Flow 1 | 106.1 | 53.93 | 245.9 | 269.4 | 331.3 | 289.9 | 356.1 | 501.7 |
| FCF margin | 8.47% | 4.09% | 11.68% | 10.83% | 11.26% | 8.77% | 10% | 13.12% |
| FCF Conversion (EBITDA) | 42.93% | 24.49% | 55.51% | 50.2% | 52.42% | 41.52% | 45.92% | 59.89% |
| FCF Conversion (Net income) | 72.19% | 55.52% | 95.1% | 98.17% | 91.99% | 66.46% | 69.39% | 83.38% |
| Dividend per Share 2 | 1.000 | 0.7500 | 1.500 | - | - | 2.452 | 2.983 | 3.059 |
| Announcement Date | 01/03/20 | 25/03/21 | 22/03/22 | 20/03/23 | 14/03/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 575 | 609.4 | 583.8 | 600.9 | 693.9 | 716.6 | 670.4 | 749.8 | 806 | 784.1 | 737.5 | 862.3 | 678.7 |
| EBITDA | - | 138.6 | - | - | - | - | 132.7 | - | 166.9 | - | - | - | - |
| EBIT 1 | 154 | 115.1 | 96.68 | 84.19 | 131.6 | 138.1 | 102.9 | 131 | 134.3 | 149.2 | 131.2 | 153.4 | 120.8 |
| Operating Margin | 26.78% | 18.89% | 16.56% | 14.01% | 18.97% | 19.27% | 15.35% | 17.47% | 16.67% | 19.03% | 17.79% | 17.79% | 17.79% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | 73.73 | 82.63 | 69.52 | 43.87 | 78.44 | 94.66 | 53.01 | 98.87 | 113.6 | 119.3 | - | - | - |
| Net margin | 12.82% | 13.56% | 11.91% | 7.3% | 11.3% | 13.21% | 7.91% | 13.19% | 14.1% | 15.22% | - | - | - |
| EPS | - | - | - | 0.4900 | 0.8700 | - | 0.5400 | - | 1.170 | 1.220 | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 22/03/22 | 19/05/22 | 18/08/22 | 10/11/22 | 20/03/23 | 24/05/23 | 08/08/23 | 09/11/23 | 14/03/24 | 13/05/24 | - | - | - |
1SAR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 952 | 1,384 | 1,681 | 1,740 | 1,738 | 1,705 | 1,676 | 1,247 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 3.852 x | 6.285 x | 3.795 x | 3.241 x | 2.75 x | 2.441 x | 2.161 x | 1.488 x |
| Free Cash Flow 1 | 106 | 53.9 | 246 | 269 | 331 | 290 | 356 | 502 |
| ROE (net income / shareholders' equity) | 9.41% | 5.92% | 14.1% | 14.2% | 13.9% | 13% | 15.3% | 16% |
| ROA (Net income/ Total Assets) | 5.23% | 2.81% | 5.89% | 5.74% | 6.45% | 6.67% | 7.36% | 8.07% |
| Assets 1 | 2,810 | 3,452 | 4,388 | 4,783 | 5,582 | 6,538 | 6,975 | 7,459 |
| Book Value Per Share 2 | 17.50 | 20.40 | 20.70 | 22.10 | 35.70 | 36.30 | 38.80 | 41.40 |
| Cash Flow per Share 2 | 3.530 | 2.130 | 4.020 | 4.910 | 6.430 | 5.680 | 6.840 | 7.780 |
| Capex 1 | 201 | 129 | 116 | 173 | 295 | 238 | 267 | 210 |
| Capex / Sales | 16.06% | 9.81% | 5.49% | 6.94% | 10.01% | 7.2% | 7.49% | 5.5% |
| Announcement Date | 01/03/20 | 25/03/21 | 22/03/22 | 20/03/23 | 14/03/24 | - | - | - |
1SAR in Million2SAR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
10
Last Close Price
160.8
SAR
Average target price
155.9
SAR
Spread / Average Target
-3.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.40% | 4.19B | |
| -32.87% | 13.6B | |
| -4.50% | 11.49B | |
| +10.41% | 10.78B | |
| +27.92% | 8.59B | |
| -9.39% | 7.29B | |
| +8.16% | 6.85B | |
| +7.51% | 6.41B | |
| +16.89% | 4.39B | |
| +36.60% | 4.22B |
- Stock Market
- Equities
- 4004 Stock
- Financials Dallah Healthcare Company
